PD‑L1 Lung (Atezolizumab), IHC
Also known as: PDL1, VENTANA® PD-L1 (SP142) Assay, SP142 (Ventana)
Use
Determining PD‑L1 expression in non‑small cell lung cancer (NSCLC) tissue can provide insight into the potential survival benefit from treatment with TECENTRIQ (atezolizumab). Specifically, PD‑L1 expression in ≥50% of tumor cells or ≥10% of tumor‑infiltrating immune cells as determined by this assay may correlate with enhanced overall survival from treatment with atezolizumab.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
Immunoassay (IHC)
Biomarkers
PD-L1
Protein
LOINC Codes
- 83057-0 - PD-L1 by SP142 Tiss Ql ImStn
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Formalin‑fixed, paraffin‑embedded tissue block, or minimum 5 unstained positively charged slides
Collection Instructions
Submit FFPE block or minimum 5 unstained positively charged slides in IHC specimen transport kit
Causes for Rejection
Baked or melted slides; previously stained slides; cytospins; tissue types other than lung cancer specimens; cytology cell block; decalcified specimens; fixatives other than formalin
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Tissue block: 5 years; Slides: 30 days |
| Refrigerated | Tissue block: 5 years; Slides: 30 days |
| Frozen | Unacceptable for both |
Other tests from different labs that may be relevant